Back to Search
Start Over
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC).
- Source :
-
Annals of Oncology . 2022 Supplement 7, Vol. 33, pS1401-S1401. 1p. - Publication Year :
- 2022
- Subjects :
- *HEPATOCELLULAR carcinoma
*PEMBROLIZUMAB
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 159078732
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.08.031